White Adipose Tissue Clocks and High Calorie Feeding
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02809482|
Recruitment Status : Completed
First Posted : June 22, 2016
Last Update Posted : July 1, 2019
|Condition or disease||Intervention/treatment||Phase|
|Healthy||Other: Eucaloric feeding Other: Overfeeding||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||10 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Basic Science|
|Official Title:||Pilot Study to Examine the Impact of Overfeeding on Peripheral Clock Gene Expression in Humans|
|Actual Study Start Date :||July 2016|
|Actual Primary Completion Date :||September 2017|
|Actual Study Completion Date :||September 2017|
Other: Eucaloric feeding
3 days of a diet designed to maintain energy balance
3 days of a diet designed to induce a 40% positive energy balance
- Expression of clock genes in adipose tissue. [ Time Frame: Measured through study completion, an average of 4 weeks. ]Gene expression measured at two time points from abdominal fat.
- Gene expression of key cellular fuel sensors thought to be controlled. and/or influenced by peripheral clocks [ Time Frame: Measured through study completion, an average of 4 weeks. ]Gene expression measured at two time points from abdominal fat.
- Expression of clock genes in blood monocytes. [ Time Frame: Measured through study completion, an average of 4 weeks. ]Gene expression measured at two time points from abdominal fat.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02809482
|United States, Colorado|
|Denver, Colorado, United States, 80045|
|Principal Investigator:||Daniel Bessesen, MD||University of Colorado School of Medicine|